Medical Condition News

RSS

Communication breakdown between nerves and muscles in SMA mouse model

Researchers at the University of Missouri have identified a communication breakdown between nerves and muscles in mice that may provide new insight into the debilitating and fatal human disease known as spinal muscular atrophy.

27 Sep 2011

Viewing computer images causes long-term changes in nerve cell connections

Viewing two-dimensional images of the environment, as they occur in computer games, leads to sustained changes in the strength of nerve cell connections in the brain.

27 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

27 Sep 2011

Smaller and faster clinical drug trials could improve gains in cancer survival

With the advent of personalised medicine, gains in cancer survival over the long term could be improved by running smaller, faster trials with less stringent evidence criteria, a researcher told the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.

26 Sep 2011

Radical change needed to deliver affordable cancer care in developed countries

Cancer is one of the leading causes of death and morbidity worldwide, and its economic burden grows year by year. In 2008, the worldwide cost of cancer due to premature death and disability, excluding direct medical costs, was estimated to be US$895 billion.

26 Sep 2011

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

IsoRay, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world's first treatment of metastasized brain cancer using IsoRay's Cesium-131 brachytherapy seeds.

26 Sep 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

People with COPD, reduced lung function more likely to develop cardiovascular disease

A new study has shown that people with chronic obstructive pulmonary disease (COPD) or people with reduced lung function are at a serious risk of developing cardiovascular disease.

26 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.

26 Sep 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011

Asthma patients admitted to hospital with H1N1 are half as likely to die from infection

People with asthma who are admitted to hospital with pandemic influenza H1N1 (swine flu) are half as likely to die or require intensive care than those without asthma, according to new research.

26 Sep 2011

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Foam injections to treat varicose veins cause less pain for patients, could save NHS money

Foam injections to treat varicose veins cause less pain for patients and could save NHS money compared with a popular alternative treatment, according to researchers at Imperial College London. The study found that foam therapy was over four times more cost-effective than laser treatment and allowed patients to resume normal activity sooner. The findings were presented today at the annual meeting of the European Vascular Society in Athens.

26 Sep 2011

Medical Condition News

Communication breakdown between nerves and muscles in SMA mouse model

Viewing computer images causes long-term changes in nerve cell connections

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Smaller and faster clinical drug trials could improve gains in cancer survival

Scientists identify a way that chemotherapy causes platelet numbers to drop

Radical change needed to deliver affordable cancer care in developed countries

World's first treatment of metastasized brain cancer uses IsoRay's Cesium-131 brachytherapy seeds

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

People with COPD, reduced lung function more likely to develop cardiovascular disease

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Asthma patients admitted to hospital with H1N1 are half as likely to die from infection

InterMune reports new data from Esbriet clinical trial on IPF

Foam injections to treat varicose veins cause less pain for patients, could save NHS money

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Effects of fruit and vegetable consumption on colorectal cancer

Study shows substantial differences in use of rectal cancer therapies across Europe

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Neurofilament light as a translational biomarker

Latest News